Unlocking Innovations: From RNA Breakthroughs to FDA Approvals - Navigating the Dynamic Landscape of Hair Loss Treatments
Hair loss can be upsetting — whether it’s through aging or as the side effect of an illness or caused by some other means. It’s natural that someone noticing they are?losing their hair?would try to stay on top of the latest innovations and treatments that come down the pipeline.
The global Alopecia Market size is expected to reach USD 16.09 billion by 2030, with a CAGR of 7.9% from 2022 to 2030.
Request for a sample copy of the report: https://www.nextmsc.com/alopecia-market/request-sample
Recently, one South Korean company released a new product in Europe that uses siRNA (small interfering RNA) technology to address hair loss at the genetic level. It targets a protein called the androgen receptor, which binds together androgens — which are male hormones —?as defined by the National Institutes of Health. Billed as the first hair loss treatment that utilizes RNA technology,?CosmeRNA was released?in Europe this May, developed by Bioneer and Sirnagen.
The FDA approved the once-daily pill called Litfulo, created by pharmaceutical giant Pfizer, for people 12 and up to treat severe alopecia areata, or at least 50% hair loss.
About 23% of patients regained 80% or more of hair coverage on their scalp after six months of treatment compared to only 1.6% of participants in the placebo group, according to trial results published by?The Lancet in April.?The most common side effects reported included headache, diarrhea, acne, rash and urticaria, a skin rash defined by itchy, red or skin-colored welts.
Contact Us:
Joseph Lawrence
领英推荐
Head - Client Engagement & Servicing
Next Move Strategy Consulting
E-Mail: [email protected]
Direct: +1-217-650-7991
You can also email us at - [email protected]
Website: www.nextmsc.com